156 results
Page 4 of 8
8-K
EX-99.1
lns6ku79
30 Jul 20
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
7:17am
8-K
EX-99.3
aq7aoce
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.2
m5iyis
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
flfq1q8aq659k2ihnn
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
S-3ASR
fub9n
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
botgttm598ktyk05uc9
30 Apr 20
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations andCOVID-19 Response
7:19am
8-K
EX-99.1
64nhjrooc fa1k1frp9
13 Feb 20
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
7:40am
8-K
EX-99.1
f7ot4lqazi5f7
13 Jan 20
Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones
6:43am
8-K
EX-99.1
dpg00404peq4pg
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.3
04k8uqbi 7k
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.2
cghn2jj7kib3wuwre
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
hh7e15j mv
22 Nov 19
Other Events
5:01pm
424B5
6ewb 19wh
8 Nov 19
Prospectus supplement for primary offering
5:03pm
8-K
EX-99.1
3lgk9
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
424B5
aiq5 8oce2
6 Nov 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
5kbg1o yyv1gqw1d41
31 Oct 19
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
7:39am